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Abstract
This study was designed to assess the safety, acceptability, pharmacokinetic (PK), and pharmacodynamic (PD)
responses to rectal administration of tenofovir (TFV) 1% vaginally formulated gel and oral tenofovir disoproxil
fumarate (TDF). This study was designed as a phase 1, randomized, two-site (United States), double-blind,
placebo-controlled study of sexually abstinent men and women. Eighteen participants received a single 300-mg
exposure of oral TDF and were then randomized 2:1 to receive a single and then seven daily exposures of rectal
TFV or hydroxyethyl cellulose (HEC) placebo gel. Safety endpoints included clinical adverse events (AEs) and
mucosal safety parameters. Blood and colonic biopsies were collected for PK analyses and ex vivo HIV-1 chal-
lenge. No serious AEs were reported. However, AEs were significantly increased with 7-day TFV gel use, most
prominently with gastrointestinal AEs ( p = 0.002). Only 25% of participants liked the TFV gel. Likelihood of use
‘‘if somewhat protective’’ was *75% in both groups. Indices of mucosal damage showed minimal changes. Tissue
TFV diphosphate (TFV-DP) Cmax 30 min after single rectal exposure was 6–10 times greater than single oral
exposure; tissue TFV-DP was 5.7 times greater following 7-day versus single rectal exposure. In vivo exposure
correlated with significant ex vivo tissue infectibility suppression [single-rectal: p = 0.12, analysis of covariance
(ANCOVA) p = 0.006; 7-day rectal: p = 0.02, ANCOVA p = 0.005]. Tissue PK–PD was significantly correlated
( p = 0.002). We conclude that rectal dosing with TFV 1% gel resulted in greater TFV-DP tissue detection than oral
dosing with reduced ex vivo biopsy infectibility, enabling PK–PD correlations. On the basis of increased gastro-
intestinal AEs, rectally applied, vaginally formulated TFV was not entirely safe or acceptable, suggesting the need
for alternative rectal-specific formulations.
Introduction
Data from North America
1 and Europe2 have dem-
onstrated increased rates of HIV infection in men who
have sex with men (MSM) and a notable prevalence of anal
intercourse (AI) by men and women in the developed3–5 and
developing world.6–8 These reports provide a clear rationale
to focus HIV prevention efforts on rectal microbicides (RMs)
as one strategy to reduce high transmission rates9 via un-
protected receptive anal intercourse (RAI).10–12
Vaginal tenofovir (TFV) 1% gel is being developed and oral
tenofovir/emtricitabine (Truvada) has been approved by the
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U.S. Food and Drug Administration for preexposure prophy-
laxis (PrEP) of HIV infection.13 Women receiving TFV 1% gel in
the Centre for the AIDS Programme of Research in South Africa
(CAPRISA) 004 study had 39% protection,14 MSM in the iPrEx
study who were given tenofovir disoproxil fumarate (TDF)/
emtricitabine (Truvada) had 44% protection,15 and ser-
odiscordant men and women in the Partners PrEP Study given
TDF or TDF/emtricitabine had between 62 and 73% protec-
tion.16 In CAPRISA 004 and iPrEx, the level of protection was
related to adherence and drug concentration.15,17 Emphasizing
the importance of this trial (as well as the related MTN-007
trial), there have been no prior studies evaluating rectal safety
of the vaginally formulated 1% TFV gel product.
The vaginal formulation of TFV 1% gel used in CAPRISA
004 and other vaginal studies is extremely hyperosmolar (3111
mOsmol/kg), almost 10-fold more than human semen.18 De-
spite this, there were no significant differences in genital tract
adverse events (AEs) in clinical trials of this formulation.14,19
However, given that hyperosmolar products can induce mu-
cosal damage in the colon,20,21 they require careful phase 1
evaluation if they are to be considered as candidate RMs.
The RMP-02/MTN-006 study design was complex, built on
the prior phase 1 RM trial (UC781)22 evaluating clinical and
mucosal safety, acceptability, multicompartmental pharma-
cokinetic and ex vivo biopsy infectibility of in vivo exposed
tissues (as a potential surrogate biomarker of product effi-
cacy). This trial demonstrates that sufficient data can be
collected in a small phase 1 trial to model pharmacokinetic–
pharmacodynamic (PK–PD) correlations for RM efficacy. As
phase 2B/3 studies are large, expensive, and time-consuming,
demonstrating preliminary evidence of product efficacy in
phase 1 trials would be very valuable in potentially reducing
the risk of subsequent failure in phase 2B/3 studies.
Materials and Methods
Objectives
The primary objective was to evaluate the systemic safety of
TFV 1% gel when applied rectally. Secondary objectives in-
cluded evaluating acceptability and mucosal immunotoxicity of
the TFV 1% gel, comparing systemic and compartmental PK
among oral TDF and rectal TFV 1% gel users. An exploratory
objective assessed the efficacy of TFV 1% gel in preventing
ex vivo infectibility of rectal tissue biopsies with HIV-1. The trial
was approved by the institutional review board at each site
[University of California at Los Angeles (UCLA), Los Angeles,
CA; Magee-Womens Research Institute (MWRI), Pittsburgh,
PA]; all participants provided written informed consent. RMP-
02/MTN-006 is registered at ClinicalTrials.gov (NCT00984971)
and is in compliance with the CONSORT (Consolidated Stan-
dards of Reporting Trials) 2010 trial reporting recommenda-
tions (www.consortstatement.org).
Design
RMP-02/MTN-006 was a phase 1, double-blind, random-
ized, placebo-controlled comparison of oral TDF (300 mg),
rectally applied TFV 1% gel, and the hydroxyethyl cellulose
(HEC) placebo gel (Fig. 1). All participants received a single
dose of oral TDF (stage 1) followed 4 weeks later (2 weeks for
sample collection postexposure and then 2 weeks for healing)
by rectally applied TFV 1% gel or the HEC gel given as a single
dose (stage 2) and, 4 weeks later, seven daily doses (stage 3),
during which six doses of the gel products were taken at
home on sequential days (with reminder calls/daily jour-
nals) with the final dose administered in the clinic under
supervision. Randomization, by study pharmacist, was a
two-part process. After enrollment, each subject was as-
signed to either the treatment or placebo arm (2:1; TFV 1%
gel:HEC gel) and also to one of two postexposure biopsy
sampling arms for mucosal safety after each exposure stage.
This reduced the number of sigmoidoscopic procedures per
participant from five to three per study stage (single oral,
single rectal, 7-day rectal) with at least 5–8 days between
biopsy collections for mucosal healing: Group ‘‘A’’ biopsied
on days 1–3 and 7–9 or group ‘‘B’’ biopsied on days 4–6 and
10–12. Each 2 weeks of biopsy sampling was followed by a 2-
week resting period between stages. Sample size (n = 18) was
based on similar phase 1 studies of topical microbicide




















































FIG. 1. Study flow diagram.
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Study participants
Study participants were healthy HIV-1-seronegative men
and women with a history of consensual RAI, willing to ab-
stain from vaginal and rectal sex during active protocol pha-
ses. Female participants were required to be using an
acceptable form of contraception.
Study products
TDF tablets (300 mg) were supplied by Gilead Sciences
(Foster City, CA). TFV 1% gel and HEC gel were supplied by
CONRAD (Arlington, VA). TFV 1% gel (weight/weight) is
tenofovir (PMPA, 9-[(R)-2-(phosphonomethoxy)propyl]ade-
nine monohydrate), formulated in purified water with edetate
disodium, citric acid, glycerin, methylparaben, propylpar-
aben, and hydroxyethyl cellulose with pH adjusted to 4–5
with an osmolarity of 3111 mOsmol/kg. The HEC placebo gel
contained hydroxyethyl cellulose as the gel thickener, puri-
fied water, sodium chloride, sorbic acid, and sodium hy-
droxide.23 The gel was isotonic with a pH of 4.4, osmolarity of
304 mOsmol/kg,24 and viscosity similar to the other micro-
bicide gel candidates. Both TFV and HEC gels were prefilled
into single-use, opaque applicators (HTI Plastics, Lincoln, NE)
containing approximately 4 ml of gel.
Study procedures
Screening included medical history, physical examination
including digital rectal examination, and collection of rectal
swabs and urine for Chlamydia trachomatis and Neisseria gonor-
rhea (CT and GC) nucleic acid amplification testing (NAAT).
Pregnancy testing in female participants [urine human chor-
ionic gonadotrophin (hCG)] was conducted at screening and all
subsequent visits. Blood was collected for clinical safety evalu-
ation (complete blood count, alanine aminotransferase, aspar-
tate aminotransferase, creatinine, phosphate) and serology
[syphilis, HIV-1, hepatitis B surface antigen (HBsAg), herpes
simplex 1 and 2]. Participants meeting inclusion/exclusion
criteria at the screening visit (V1) proceeded to the enroll-
ment visit (V2) for a focused physical/rectal examination,
randomization (both for drug/placebo gel product and bi-
opsy schedule), and behavioral questionnaire completion.
Safety and sexually transmitted infection (STI) blood/urine
(urine hCG for female participants) samples were collected.
Rectal swabs were collected to assess changes in rectal mi-
croflora; rectal sponges were inserted to collect rectal secre-
tions for cytokines/chemokines and baseline (unexposed)
pharmacokinetics (PK). Self-collected vaginal swabs were
collected for pH, Gram stain, bacterial vaginosis (BV); vag-
inal sponges were used for baseline (unexposed) PK. Al-
though results are not reported, positive STIs, pregnancy,
and BV detection were exclusion criteria. Participants then
received a Normosol-R pH 7.4 enema with a sample of feces
collected from effluent for fecal calprotectin measurement. A
flexible sigmoidoscope was then inserted into the rectum to
*5 cm from the anal margin, where 50 cc of Normosol so-
lution was slowly instilled. After 30 s, at least 25–30 ml of
lavage fluid was collected via endoscopic aspiration to as-
sess epithelial sloughing. The endoscope was then advanced
to *15 cm, where *17 biopsies were collected for histology,
flow cytometry, ex vivo tissue infectibility assays, and base-
line PK.
After clinician-administered single-dose oral (V3; stage 1)
and single-dose topical (V7; stage 2), participants received the
same evaluations as V2 but endoscopic samples were col-
lected approximately 30 min after product exposure. Addi-
tional blood and vaginal/rectal sponges were collected at
30 min, + 2 h, + 4 h, and + 24 h for PK. On the basis of ran-
domization, participants underwent further blood, vaginal/
rectal sponges and sigmoidoscopic biopsy sampling for
mucosal injury, flow cytometry, PK, and ex vivo tissue in-
fectibility evaluations on either days 1–3, 4–6, 7–9, or 10–12
post-V3 and post-V7. For the 7-day exposure (V11; stage 3),
vaginal/rectal sponges were collected for PK and participants
received a 6-day supply of applicators. The seventh dose was
administered by clinic personnel (V12) with sample collec-
tions for STIs, HIV serology, and PK 30 min later with 24-h PK
collections as described above (V13).
Clinical safety
Emergent AEs were graded using the Division of AIDS Table
for Grading the Severity of Adult and Pediatric AEs, version 1.0,
December 2004 as well as Addenda 1 and 3 (Female Genital
Grading Table for Use in Microbicide Studies and Rectal Grading
Table for Use in Microbicide Studies, respectively) (http://rsc
.tech-res.com/safetyandpharmacovigilance/). In cases in which
an AE was covered in both tables, Addenda 1 and 3 were used.
Mucosal safety
Histology. A semiquantitative scoring system adapted for
use in rectal microbicide trials22 was used to characterize
potential product associated injury with a scale of 1 (normal)
to 5 (mucosal erosion or ulceration).
Fecal calprotectin. Fecal calprotectin, an indirect index of
mucosal inflammation, was measured with a commercial
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FIG. 2. CONSORT (Consolidated Standards of Reporting
Trials) enrollment summary. STI, sexually transmitted in-
fection.
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Epithelial sloughing. Epithelial sloughing was evaluated
by a modification of a previously described technique.26 La-
vage samples were scored as either 0 or 1 (absence or presence
of epithelial sheets) for a total score from 0 to 4.
Rectal microflora. Rectal microflora were characterized
(baseline to V13) on the basis of previously described semi-
quantitative culture analysis.22
Mucosal T cell phenotype. Mucosal mononuclear cells
were isolated from rectal biopsies, using mechanical/enzyme
digestion as previously described.27 Monoclonal antibodies
selection was the same as in RMP-01,22 supplied by BD Im-
munocytometry Systems (BDIS, Mountain View, CA). Once
stained, all samples were shipped to UCLA for single-site
analysis using a FACSCalibur flow cytometer (BDIS, Moun-
tain View, CA) with analysis using CellQuest Pro software
(BDIS).
Luminex analysis of rectal secretions. The MILLIPLEX
MAP kit (Millipore, Billerica, MA) was used to detect
RANTES (regulated on activation, normal T cell expressed
and secreted), macrophage inflammatory protein (MIP)-1a,
tumor necrosis factor (TNF)-a, interferon (IFN)-c, interleukin
(IL)-12 (p-40), IL-6, and IL-1b, using Luminex 100 IS (Lumi-
nex, Austin, TX) as previously described.22
Product acceptability and adherence
Acceptability was measured as the proportion of partici-
pants who reported via computer-assisted self-interview
(CASI): (1) overall liking of gel, (2) ease of use, and (3) likeli-
hood of future use. Quantitative measures used a 10-point
Likert scale (1, low; 10, high). Participants completed a diary
documenting gel use during the 6-day home-use period. Re-
turned diaries were cross-validated with counts of returned
used/unused gel applicators. Adherence was defined as the
proportion of times the product was used out of all possible
uses.
PK analyses
Only plasma TFV and rectal tissue TFV-DP PK results are
presented here. Data and PK correlations between the other
compartments will be presented separately (unpublished re-
sults). Plasma TFV and tissue TFV-DP concentrations were
determined by previously described liquid chromatography-
tandem mass spectrometry (LC-MS/MS) methods validated
for all matrices at the Johns Hopkins Clinical Pharmacology
Analytical Laboratory28,29 and met U.S. Food and Drug Ad-
ministration (FDA) bioanalytical validation criteria.30 Ana-
lyses/interpretations of PK data were performed by the
University of North Carolina Center for AIDS Research (UNC
CFAR) Clinical Pharmacology/Analytical Chemistry Core.
PD analyses (ex vivo tissue infectibility)
At baseline and each specified time point after product
exposure, endoscopic biopsies were collected in 50 ml of
RPMI (with 1.125 lg/ml of Fungizone and 50 mg/ml of Zo-
syn), transported to the laboratory for ex vivo infection [2 h;
common viral stock of R5 HIV-1BaL (10
4 TCID50)], as previ-
ously described.31–34 Supernatants for p24 quantification were
collected every 3 days during each participant’s 14-day in-
fectibility studies (days 1, 4, 7, 11, and 14). Results are reported
as cumulative p24 (National Cancer Institute, Bethesda, MD).
The lower limit of quantification (LLOQ) of the assay was
10 pg of p24 per milliliter.
Analysis of study outcomes
Primary safety outcomes were protocol-defined as the fre-
quency of AEs of grade 2 or higher. Between-group compar-
isons of numbers of subjects having any AEs were done using
Fisher’s exact test; for total number of AEs, analyses were
done assuming a Poisson model. Given the small sample size,
there was limited power to detect differences between study
arms. Acceptability was defined as the proportion of partici-
pants reporting a high likelihood of future product use de-
fined by a rating in the upper third of a 10-point Likert scale.
Changes in mucosal safety parameters within groups were
assessed by comparisons before (Visit 2-baseline) to 30 min-
utes after product exposure using two-sided paired t-tests or
Wilcoxon tests with a = 0.05. Cumulative day 14 changes in
HIV-1 p24 tissue infectibility assays were assessed similarly
with a = 0.05. Differences in mucosal safety parameters and
cumulative p24 values between experimental groups were
assessed using ANCOVA models adjusting for the baseline
measurements. Pharmacokinetic parameters were estimated
using noncompartmental methods (Phoenix WinNonlin Pro
5.2; Certara, L.P., St. Louis, MO). Maximum concentration
(Cmax), time at maximum concentration (Tmax), and concen-
tration 24 h after dosing (C24h) were determined by visual in-
spection of subject profiles, and used the log-linear trapezoidal
method to calculate the area under the time–concentration
curve over 24 h (AUC24h). Detectable concentrations below the
limit of quantification were imputed as 50% of the LLOQ. A
linear regression was used to correlate detectable rectal tissue
TFV-DP (log10 fmol/mg) in the TFV-treated group with con-
cordant tissue infectibility (cumulative p24 log10 pg/ml levels,
averaged across quadruplicate rectal biopsies) after single oral,
single topical, and 7-day topical exposures.
Results
Enrollment; participant disposition
Twenty-one participants were randomized (15 at UCLA, 6
at MWRI), with 3 (UCLA) withdrawn before receiving any
product (Fig. 2). The 18 enrolled participants received oral
product and then rectal products according to their random-
ization (Fig. 1). All 18 completed all study visits (100% re-
tention; 144 flexible sigmoidoscopies; > 2300 biopsies).
Participants were 14 males (78%) and 4 females (22%) with a
median age of 45 years (range, 22–66 years); 11% African-
American, 56% white, and 33% Hispanic (Table 1).
Adverse events
There were no serious or procedure-related AEs. After
product exposure, the nonrandomized, single oral exposure
stage identified 30 grade 1, 5 grade 2, and 2 grade 3 AEs (Table
2). During the randomized, single topical exposure stage there
were 20 grade 1, 10 grade 2, and 0 grade 3 AEs with no sig-
nificant differences between groups in overall or gastrointes-
tinal (GI)-specific AEs. During the randomized, 7-day topical
exposure stage: 49 grade 1, 7 grade 2, and 6 grade 3 AEs were
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reported (all resolved). A significant difference in number of
AEs, especially GI-related AEs, was present in the TFV-treated
group ( p = 0.002 for GI AEs during 7-day exposure). Regarding
the seven grade 2 AEs in the 7-day exposure, six occurred in
three (of twelve) TFV-treated subjects and one occurred in 1 of 6
in a placebo-treated subjects (all minor, non–life-threatening)
( p = 1.0). All six grade 3 AEs, five of which were GI related,
occurred in two of twelve TFV-treated subjects ( p = 0.53).
Mucosal safety
Epithelial sloughing, histopathology, rectal microflora, fe-
cal calprotectin, and flow cytometry. No differences were
observed within groups compared with baseline or between
groups, at any time point postexposure.
Secreted rectal cytokines. There were no significant
changes in HEC controls at any stage using either paired
t-tests or Wilcoxon signed rank tests. Following oral TDF,
there were no significant changes using paired t-tests; how-
ever, Wilcoxon tests identified IL-1b ( p = 0.02) and TNFa
( p = 0.03) suppression. Following single-rectal exposure, t-tests
showed marginally significant suppression of IL-1b ( p =
0.046); with Wilcoxon tests, IL-1b suppression was more sig-
nificant ( p = 0.003) and marginally significant changes emerge
in MIP-1a ( p = 0.025) and TNFa ( p = 0.03). Following 7-day
rectal exposure, t-tests show marginally significant suppres-
sion of IL-1b ( p = 0.04) and MIP-1a ( p = 0.03). When using
Wilcoxon tests, the significance increased (IL-1b: p = 0.002;
MIP-1a: p = 0.004) and marginally significant suppression of
IL-6 ( p = 0.04) and TNFa ( p = 0.03) was identified. Inclusion of
results from both methods is intended to provide full in-
formation from a small trial designed to identify any changes.
Product acceptability and adherence
Of the participants in the tenofovir group, 67% versus 83%
in the HEC placebo group found the gel easy to use. However,
only 25% of participants receiving TFV gel versus 50% in the
HEC placebo group reported ‘‘liking the product very much.’’
Despite this, 75% of the TFV gel group and 67% in the HEC
group stated that they would be ‘‘very likely’’ to use the gel in
the future if it provided some protection. Self-reports of 6-day
at-home use of dispensed applicators were cross-validated
with returned used/unused applicator counts; these coin-
cided in 16 of 18 cases. Using these cross-checks, 83% of all
participants (92% in the tenofovir arm) were fully adherent
during this stage.
Pharmacokinetics
Plasma tenofovir (TFV). Concentrations of plasma TFV
Cmax and AUC24h were 23- and 30-fold higher after the single
oral exposure compared with single rectal exposure. With oral
dosing, the median AUC24h was 2003 ng$h/ml with a Cmax of
246 ng/ml at 2 h postdose. In contrast, for single rectal expo-
sure, the AUC24h was 52 ng  h/ml with a Cmax of 8 ng/ml
occurring 0.3 h postdose (Fig. 3A). Seven-day rectal exposures
were similar to single-rectal exposures in plasma concentra-
tions: AUC24h was 35 ng  h/ml with a Cmax of 5 ng/ml at
0.3 h postdose. Plasma C24h was detectable in 100% of single
oral exposure subjects (median concentration, 36 ng/ml) but
detectable in *70% of single rectal exposure subjects (median
concentration. 0.3 ng/ml) and *88% after 7-day rectal expo-
sure (median concentration, 0.9 ng/ml), indicating negligible
accumulation during this time period.
Tissue tenofovir diphosphate (TFV-DP). After single oral
and single rectal exposures, rectal biopsies from the 18 par-
ticipants were collected at three time points from 30 min to 14
days (alternating days, for safety reasons). Tmax results reflect
only the designated time points (30 min, 1–3 days or 4–6 days,
7–10 days or 10–12 days).
TFV-DP was not detected in any tissue samples 30 min after
oral exposure (n = 18) but was detected in 95% of single rectal
exposed (n = 11/12) as well as 7-day rectal exposed (n = 12/12)
tissue samples (Fig. 3B).
After 24 h, eight oral-exposed subjects had a median TFV-
DP concentration of 29 fmol/mg (range, 0–992). This was Tmax
for seven of eight subjects with detectable tissue TFV-DP; the
eighth subject’s Tmax occurred on day 7. Tissue concentrations
of any TFV-DP after single oral exposure were detected in 3 of
18 subjects out to 6–7 days postexposure (median, 106 fmol/mg;
range, 0–117).
In contrast, after single rectal exposure (n = 12), the median
30-min TFV-DP concentration was 176 fmol/mg (range,
0–1229); by 24 h, five of six subjects sampled had a higher
median TFV-DP tissue concentration of 285 fmol/mg (range,
0–490). These concentrations were approximately 6- to 10-fold
higher than after the single oral exposure. Tmax occurred at
30 min in 9 of 12, with only 2 of 12 having their Tmax at 24h
(1 of 12 never had measureable TFV-DP). TFV-DP concen-
trations were detected out to 6–7 days postexposure in 2 of 12
subject samples.
After 7-day rectal exposure, where tissue samples were
only obtained 30 min after the seventh administered topical
gel, TFV-DP was detected in all 12 subject biopsies (me-
dian, 789 fmol/mg; range, 56–7187). The accumulation ra-
tios (TFV-DP tissue concentration at 30 min after seventh
exposure/TFV-DP tissue concentration 30 min after single








Participants enrolled 18 12 6
Age (years)
Mean (STD) 42.1 (11.4) 41.3 (11.9) 43.7 (10.2)
Gender
Male 14 (78%) 10 (83%) 4 (67%)
Female 4 (22%) 2 (17%) 2 (33%)
Latino or of Hispanic origin
Yes 5 (28%) 3 (25%) 2 (33%)
No 13 (72%) 9 (75%) 4 (67%)
Race
Asian 0 0 0
Black or
African-American




White 15 (83%) 10 (84%) 5 (83%)
Other 1 (6%) 1 (8%) 0
HEC, hydroxyethyl cellulose; STD, standard deviation.
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exposure) in 11 of 12 subjects yielded a median accumulation
ratio of 5.7 (0.3–23) demonstrating TFV-DP accumulation
over time.
Pharmacodynamics
At baseline, all participants’ rectal biopsies were infectible
ex vivo with a viral titer of 104 TCID50 HIV-1BaL, with a known
range of assay variability. No significant suppression of ex vivo
infection was seen at any time point after single oral exposure
(Fig. 4A and B show data for 30 min and 24hr post-exposure).
After single rectal exposure, there was a nonsignificant de-
clining p24 trend in the tenofovir group ( p = 0.12; effect size,
0.49) but the ANCOVA comparing suppression in TFV-
exposed to placebo was significant at p = 0.006 (Fig. 4C and D).
Seven-day TFV rectal exposure showed significant suppres-
sion of ex vivo biopsy infectibility versus placebo ( p = 0.02;
effect size, 0.80) with the ANCOVA comparing TFV-exposed
to placebo significant at 30 min after final exposure ( p = 0.005)
(Fig. 4E and F). Interestingly, all participants with reduced
tissue infectibility ex vivo also showed suppression in IL-1b,
TNFa and MIP-1a secreted rectal cytokines.
PK–PD correlation (tissue TFV-DP with ex vivo biopsy
infectibility). As shown in Fig. 3C, during each exposure
stage, detectable rectal tissue TFV-DP concentrations (at least
one of five time points sampled over 14 days postdosing) were
found in 9 of 18 (50%) for single oral, 11 of 12 (95%) for single
rectal, and 12 of 12 (100%) for 7-day rectal-exposed partici-
pants. Analyzing all paired TFV-exposed samples, tissue
TFV-DP levels and ex vivo biopsy infectibility were correlated.
A significant ( p = 0.0022), negative (slope = –0.5142 – 0.1561)
linear dose–response relationship was found (Fig. 3C). Al-
though the data were variable (r2 = 0.23), a clear relationship
Table 2. Number of Participants with Adverse Events
TFV 1% gel (topical) HEC placebo gel (topical)
TDF (oral) Single dose 7-day dose Single dose 7-day dose
Participants enrolled 18 12 6
Participants with one or more AEs (all)
Grade 1: Mild 11 (30) 4 (11) 12 (41) 4 (9) 4 (8)
Grade 2: Moderate 3 (5) 4 (6) 3 (6) 1 (4) 1 (1)
Grade 3: Severe 2 (2) 0 2 (6) 0 0
Participants with gastrointestinal AEs
Grade 1: Mild 7 (15) 4 (6) 12 (34) 3 (5) 1 (5)
Grade 2: Moderate 0 2 (4) 2 (3) 1 (4) 1 (1)
Grade 3: Severe 0 0 2 (5) 0 0
Participant’s specific gastrointestinal AEs
Abdominal bloating (G1) 3 (3) 0 4 (8) 0 1 (1)
Abdominal bloating (G2) 0 1 (1) 0 1 (1) 0
Abdominal bloating (G3) 0 0 1 (1) 0 0
Abdominal pain/cramps (G1) 1 (1) 2 (2) 2 (2) 1 (1) 1 (1)
Abdominal pain/cramps (G2) 0 1 (1) 0 1 (1) 1 (1)
Abdominal pain/cramps (G3) 0 0 1 (1) 0 0
Colon polyps (G1) 4 (4) 0 1 (1) 0 0
Constipation (G1) 1 (1) 0 0 0 0
Defecation urgency (G1) 0 0 4 (6) 0 0
Defecation urgency (G2) 0 1 (1) 1 (1) 0 0
Defecation urgency (G3) 0 0 2 (2) 0 0
Diarrhea (G1) 2 (3) 1 (1) 6 (7) 0 0
Diarrhea (G2) 0 0 2 (2) 0 0
Fissure (anal) (G1) 1 (1) 0 0 0 0
Flatulence (G1) 0 0 2 (2) 0 0
Flatulence (G2) 0 1 (1) 0 0 0
Hemorrhoid 0 0 0 1 (1) 0
Loose stool (G1) 0 0 0 1 (1) 0
Loss of appetite (G1) 1 (1) 0 0 0 0
Mucosal red spots (G1) 0 1 (1) 0 2 (2) 0
Nausea (G1) 1 (1) 2 (2) 3 (5) 0 1 (1)
Nausea (G2) 0 0 0 1 (1) 0
Rectal discharge (G1) 0 0 1 (1) 0 0
Rectal pain (G1) 0 0 1 (1) 0 1 (1)
Tenesmus (G1) 0 0 1 (1) 0 1 (1)
Tenesmus (G2) 0 0 0 0 0
Tenesmus (G3) 0 0 1 (1) 0 0
Vomiting (G2) 0 0 0 1 (1) 0
Only AEs following product exposure are reported. Some individuals report more than 1 AE. For convenience all Grade 3 AEs are listed in
bold.
AE, adverse event; TDF, tenofovir disoproxil fumarate; TFV, tenofovir; HEC, hydroxyethyl-cellulose.
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was found between decreased infectibility of ex vivo biopsies
and increased tissue TFV-DP concentration.
Discussion
This study demonstrates that the vaginal formulation of
TFV 1% gel is neither entirely safe (based on gastrointestinal
AEs) nor entirely acceptable for rectal use, indicating the need
for development of a rectal-specific formulation. This trial is
also the first trial to compare single-exposure oral TDF with
single-exposure rectal TFV for mucosal toxicity, PK, and
ex vivo infectibility. Single rectal administration of TFV 1% gel
was associated with > 6–10 times greater local tissue con-
centration of TFV-DP than single oral administration, with
minimal plasma TFV concentrations and with significantly
lower levels of ex vivo tissue infection compared to the con-
trols. After 7-day rectal exposure to TFV gel, rectal biopsies
contained *5.7-fold more TFV-DP than single rectal exposure
and also demonstrated significantly reduced tissue infect-
ibility. This inversely correlated with the amount of drug
found in the tissue. These latter points demonstrate the po-
tential to generate PK–PD correlations in a phase 1 rectal
microbicide trial.
Although there were no significant differences in total or
gastrointestinal-related grade 2 AEs after single rectal expo-
sure to TFV or HEC gels, 7-day exposure to TFV did produce
more grade 2 and 3 AEs than placebo. Importantly, all six
reported grade 3 AEs were in two (of 12) TFV gel participants;
five of six were GI related. It is likely that these AEs, especially
the grade 3 AEs, were caused by the high osmolality of the
vaginally formulated TFV 1% gel.
Despite these clinical findings as well as publications asso-
ciating the use of hyperosmolar products rectally with mucosal
damage,20 TFV 1% gel was not associated with any significant
index of mucosal damage overall.35 Using paired t-tests, some
rectal-secretion cytokines (IL-1b, TNFa, IL-6, MIP-1a; all often
classified as ‘‘pro-inflammatory’’ were shown to be reduced in
the TFV-treated groups at different study stages. Given the
small sample size it is of interest that when using the uncor-
rected cytokine results, all the subjects with reduced ex vivo
infectibility at the end of the 7-day exposure period also ex-
pressed generally reduced mucosal cytokine levels (above).
Although these two ‘‘proinflammatory’’ cytokines are usually
associated with increased mucosal replication, their reduction
in well-suppressed HIV-seropositive patients (even compared
with healthy control subjects) has been reported.36,37 Studies
seeking to elucidate the mechanisms of the antiviral effective-
ness of tenofovir have reported the in vitro stimulation of a
FIG. 3. Pharmacokinetics (PK): Tenofovir (TFV) levels in
plasma and tenofovir diphosphate (TFV-DP) level in rectal
tissue over 24 h postexposure. (A) Plasma (TFV): The Tmax
and subsequent decay for detection of plasma TFV after
single oral, single/topical–rectal, and 7-day topical–rectal are
shown. Single oral exposures peak later and, at 24 h, plasma
concentrations are *98% higher than either of the topical
rectal exposures. (B) Tissue (TFV-DP): Detectable concen-
trations of TFV-DP from homogenized tissue biopsies ac-
quired within the first 24 h for the single oral, single topical/
rectal exposures and 30 min after the last of the 7-day
topical rectal exposures are shown. (C) Pharmacokinetic–
pharmacodynamic (PK–PD) correlation of tissue TFV-DP
concentration with ex vivo tissue infectibility: The linear
correlation of tissue TFV-DP (log10 fmol/mg) and infectivity
[defined by log10-transformed cumulative p24 (pg/ml) on
day 14] is shown for subjects with detectable tissue TFV-DP
after single oral (n = 18; 5 time points sampled over 14 days
postexposure*), single topical exposure (n = 12, five time
points sampled over 14 days postexposure*), and 7 days
topical exposure (n = 12, 30 min after final exposure) to te-
nofovir product. [*Oral exposure: 18 subjects at 30 min and 9
subjects (group A or B) at 1–3, 4–6, 7–9, and 10–12 days;
single topical/rectal: 12 subjects at 30 min and 6 subjects
(group A or B) at 1–3, 4–6, 7–9, and 10–12 days.]
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variety of chemokines and cytokines, including TNF-a and IL-
1b.38 Combined with reports from MTN-007,39 these findings
merit ongoing attention in future trials. Although the partici-
pants demonstrated high adherence by the measures used, it
was quite clear that only a minority of TFV gel recipients liked
the product, providing an additional, user-based rationale to
develop/test rectal specific formulations.
Not surprisingly, single rectal administration of TFV 1% gel
resulted in much higher, short-term tissue concentrations of
intracellular TFV-DP than single oral TDF. Repeated rectal
exposures further increased tissue TFV-DF. These findings are
similar to the observations in MTN-001, where administration
of vaginal TFV 1% gel resulted in significantly greater tissue
concentrations of TFV-DP than oral dosing with Truvada.40
Administration of a single TDF oral exposure provided no
reduction in ex vivo biopsy infectibility. However, both single-
rectal and 7day-rectal TFV gel exposure showed significant
ex vivo suppression of tissue infectibility. Although these in-
fectibility assays are only potential, laboratory-based, efficacy
indicators, the lack of significant ex vivo suppression after single
oral exposure focuses attention on better characterizing the PK–
PD relationships with regard to single, pericoital administration
of either or both oral or topical–rectal tenofovir-based PrEP for
HIV prevention.
The PK and PD data acquired during this trial, together
with similar data from our previous rectal assessment of
UC781 gel (RMP-01),22 provide an important contribution to
the field of HIV prevention, demonstrating that meaningful
PK–PD correlations can be generated in phase 1 microbicide
trials. In the case of UC781 gel, these data have enabled the
development of a PK–PD model to determine effective tissue
concentrations (ECs) needed to reduce ex vivo tissue infect-
ibility by 50–95% (EC50,90,95).
41
Overall, this study suggests that optimization of the vagi-
nally formulated TFV 1% gel is needed for use as a rectal mi-
crobicide.21 However, it is clear that rectal administration of an
antiretroviral gel such as TFV is an extremely effective way to
deliver high concentrations of active drug to highly vulnerable
rectal mucosa. This study also demonstrates that intensified
phase 1 trials including acceptability assessments, focused
mucosal safety biomarkers, multicompartment PK, and ex vivo
infectibility assays are feasible with high participant retention.
The data from these early-in-development types of studies will
allow optimization of product profiles before moving candidate
microbicides into later-stage development.
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